IR@PKUHSC  > 北京大学药学院
学科主题药学
Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin
Zheng, Dandan; Duan, Cunxian; Zhang, Dianrui1; Jia, Lejiao; Liu, Guangpu; Liu, Yue; Wang, Feihu; Li, Caiyun; Guo, Hejian; Zhang, Qiang2
关键词Galactosylated chitosan Nanoparticles Oridonin Tumor targeting
刊名INTERNATIONAL JOURNAL OF PHARMACEUTICS
2012-10-15
DOI10.1016/j.ijpharm.2012.06.039
436期:1-2页:379-386
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
资助者National Basic Research Programme of China (973 Programme) ; National Basic Research Programme of China (973 Programme)
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]GRAFTED-PEGYLATED-CHITOSAN ; TISSUE DISTRIBUTION ; ASIALOGLYCOPROTEIN RECEPTOR ; DRUG-DELIVERY ; HEPG2 CELLS ; NANOCAPSULES ; PACLITAXEL ; PHARMACOKINETICS ; PERMEABILITY ; ENHANCEMENT
英文摘要

In this study, oridonin-loaded nanoparticles coated with galactosylated chitosan (ORI-GC-NP) were prepared for tumor targeting and their characteristics were evaluated for the morphologies, particle size and zeta potential. Oridonin-loaded nanoparticles (ORI-NP) without galactosylated chitosan were prepared as a control. The entrapment efficiency of ORI-GC-NP and ORI-NP were 72.15% and 85.31%, respectively. The in vitro drug release behavior from nanoparticles displayed biphasic drug release pattern with initial burst release and consequently sustained release. Next, the pharmacokinetics and tissue distribution of ORI-GC-NP, ORI-NP and ORI solution were carried out. Pharmacokinetic analysis showed that ORI-GC-NP and ORI-NP could prolong the drug plasma levels compared with ORI solution. Meanwhile, the distribution of ORI-GC-NP to liver was higher than that of ORI-NP and free drug. In conclusion, ORI-GC-NP, as a promising intravenous drug delivery system for ORI, could be developed as an alternative to the conventional ORI preparations. (c) 2012 Elsevier B.V. All rights reserved.

语种英语
所属项目编号2009CB930300
资助者National Basic Research Programme of China (973 Programme) ; National Basic Research Programme of China (973 Programme)
WOS记录号WOS:000308597600042
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65545
专题北京大学药学院
作者单位1.Shandong Univ, Dept Pharmaceut, Coll Pharm, Jinan 250012, Shandong, Peoples R China
2.Peking Univ, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Zheng, Dandan,Duan, Cunxian,Zhang, Dianrui,et al. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS,2012,436(1-2):379-386.
APA Zheng, Dandan.,Duan, Cunxian.,Zhang, Dianrui.,Jia, Lejiao.,Liu, Guangpu.,...&Zhang, Qiang.(2012).Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin.INTERNATIONAL JOURNAL OF PHARMACEUTICS,436(1-2),379-386.
MLA Zheng, Dandan,et al."Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin".INTERNATIONAL JOURNAL OF PHARMACEUTICS 436.1-2(2012):379-386.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zheng, Dandan]的文章
[Duan, Cunxian]的文章
[Zhang, Dianrui]的文章
百度学术
百度学术中相似的文章
[Zheng, Dandan]的文章
[Duan, Cunxian]的文章
[Zhang, Dianrui]的文章
必应学术
必应学术中相似的文章
[Zheng, Dandan]的文章
[Duan, Cunxian]的文章
[Zhang, Dianrui]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。